Although the resistance factor BCLxL-BAK complex also decreased for BC-7064-R, the weakened BCL2 dependence led to an estimated score of 0.36, explaining the relapse of this specific blood cancer (Fig. 4h,i). The gene discussed is BCL2; the disease is hematopoietic and lymphoid system neoplasm.